These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

775 related articles for article (PubMed ID: 18049028)

  • 1. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
    Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
    Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness.
    Yasmin ; McEniery CM; Wallace S; Dakham Z; Pulsalkar P; Maki-Petaja K; Ashby MJ; Cockcroft JR; Wilkinson IB
    Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):372. PubMed ID: 15556929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The changes and impact factors of carotid-femoral and carotid-radial pulse wave velocity in patients with essential hypertension].
    Hua Q; Tan J; Liu DX; Wen J; Xing XR
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Dec; 33(12):1088-91. PubMed ID: 16563276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
    Tayebjee MH; Karalis I; Nadar SK; Beevers DG; MacFadyen RJ; Lip GY
    Am J Hypertens; 2005 Mar; 18(3):325-9. PubMed ID: 15797648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of perindopril on elastic and structural properties of large arteries in essential hypertension.
    Lacourcière Y; Béliveau R; Conter HS; Burgess ED; Lepage S; Pesant Y; Spence JD; Asmar R; Carrière S; Plante GE;
    Can J Cardiol; 2004 Jun; 20(8):795-9. PubMed ID: 15229761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
    Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
    Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
    Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Collagen type-I degradation is related to arterial stiffness in hypertensive and normotensive subjects.
    McNulty M; Mahmud A; Spiers P; Feely J
    J Hum Hypertens; 2006 Nov; 20(11):867-73. PubMed ID: 16598292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinase-9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension.
    Zhou S; Feely J; Spiers JP; Mahmud A
    J Hum Hypertens; 2007 Nov; 21(11):861-7. PubMed ID: 17581602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collagen metabolism in extracellular matrix may be involved in arterial stiffness in older hypertensive patients with left ventricular hypertrophy.
    Ishikawa J; Kario K; Matsui Y; Shibasaki S; Morinari M; Kaneda R; Hoshide S; Eguchi K; Hojo Y; Shimada K
    Hypertens Res; 2005 Dec; 28(12):995-1001. PubMed ID: 16671339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents.
    Głowińska-Olszewska B; Urban M
    Metabolism; 2007 Jun; 56(6):799-805. PubMed ID: 17512313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
    Florys B; Głowińska B; Urban M; Peczyńska J
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative association between serum levels of matrix metalloproteinases-2 and -9 and aortic stiffness in healthy adults.
    Vlachopoulos C; Aznaouridis K; Dima I; Ioakeimidis N; Vasiliadou C; Zervoudaki A; Gialernios T; Stefanadis C
    Int J Cardiol; 2007 Nov; 122(3):232-8. PubMed ID: 17289174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
    Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W
    Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
    Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals.
    Yasmin ; McEniery CM; O'Shaughnessy KM; Harnett P; Arshad A; Wallace S; Maki-Petaja K; McDonnell B; Ashby MJ; Brown J; Cockcroft JR; Wilkinson IB
    Arterioscler Thromb Vasc Biol; 2006 Aug; 26(8):1799-805. PubMed ID: 16709939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
    Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.